Several multikinase inhibitors have established therapeutic benefit across advanced thyroid cancers. However, treatment-related adverse events (trAEs) are impactful in this patient population and may reduce the efficacy of these drugs, according to Lori J. Wirth, MD, Associate Professor, Harvard Medical School, and Medical Director, Head and Neck Oncology, Massachusetts General Hospital Cancer Center, at the NCCN 2021 Virtual Annual Conference. Gene-specific therapies are now demonstrating potent efficacy and improved tolerability in RET- and NTRK‐driven thyroid cancers, as well as in BRAF V600E–mutant anaplastic thyroid carcinomas (ATCs), and drugs that target these specific alterations have emerged as new standard-of-care therapies.
Durante C , Haddy N , Baudin E , et al.. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892–2899.
Barbet J , Campion L , Kraeber-Bodere F , et al.. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005;90:6077–6784.
Lin B , Ma H , Ma M , et al.. The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis. Am J Transl Res 2019;11:5888–5896.
Brose MS , Nutting CM , Jarzab B , et al.. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014 384:319–328.
Schlumberger M , Tahara M , Wirth LJ , et al.. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372:621–630.
Wells SA , Robinson BG , Gagel RF , et al.. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30:134–141.
Elisei R , Schlumberger MJ , Muller SP , et al.. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31:3639–3646.
Zehir A , Benayed R , Shah RH , et al.. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017;23:703–713.
Shah MH , Wei L , Wirth LJ , et al.. Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma [abstract]. J Clin Oncol 2017;15(Suppl):Abstract 6022.
Subbiah V , Kreitman RJ , Wainberg ZA , et al.. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol 2018;36:7–13.
Ciampi R , Romei C , Ramone T , et al.. Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing. iScience 2019;20:324–336.
Wirth LJ , Sherman E , Robinson B , et al.. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 2020;383:825–835.
Drilon A , Oxnard GR , Tan DSW , et al.. Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer. N Engl J Med 2020;383:813–824.
Hu M , Subbiah V , Wirth LJ , et al.. Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC) [abstract]. Ann Oncol 2020;31(Suppl 4):Abstract 19130.
- Search Google Scholar
- Export Citation
Hu M Subbiah V Wirth LJ Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC) [abstract]. Ann Oncol 2020; 31( Suppl 4):Abstract 19130.
Hong DS , DuBois SG , Kummar S , et al.. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 2020;21:531–540.
Cabanillas ME , Drilon A, Farago AF , et al.. Larotrectinib treatment of advanced TRK fusion thyroid cancer [abstract]. Ann Oncol 2020;31(Suppl 4):Abstract 1916P.
Solomon BJ , Tan L , Lin JJ , et al.. RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies. J Thorac Oncol 2020;15:541–549.
Lin JJ , Liu SV , McCoach CE , et al.. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer. Ann Oncol 2020;31:1725–1733.
The Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159:676–690.
Yoo SK , Lee S, Kim SJ , et al.. Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers. PLoS Genet 2016;12:e1006239.
Gopal RK , Kübler K , Calvo SE , et al.. Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in Hürthle cell carcinoma. Cancer Cell 2018;34:242–255.e5.
Ganly I , Makarov V , Deraje S , et al.. Integrated genomic analysis of Hürthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes. Cancer Cell 2018;34:256–270.e5.
Landa I , Ibrahimpasic T , Boucai L , et al.. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 2016;126:1052–1066.